Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paliperidone palmitate - Johnson & Johnson

Next Previous
Drug Profile

Paliperidone palmitate - Johnson & Johnson

Alternative Names: BYANNLI; Invega Hafyera; Invega Sustenna; Invega Trinza; Paliperidone palmitate 1-month; Paliperidone palmitate 3-month; Paliperidone palmitate 6-month; R0-92670; RO-92670; Sustenna; Trevicta; Xeplion

Latest Information Update: 16 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson
  • Developer Janssen; Janssen Pharmaceutical KK; Johnson & Johnson; Xian-Janssen
  • Class 2 ring heterocyclic compounds; Antipsychotics; Fluorobenzenes; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 16 Jan 2025 No development reported - Phase-III for Schizophrenia (Treatment-experienced) in Russia, Taiwan, Malaysia, Southern Africa, Hong Kong, Turkey (IM)
  • 16 Jan 2025 No development reported - Phase-III for Schizophrenia in Hong Kong, Russia (IM)
  • 07 Jan 2025 No development reported - Phase-III for Schizophrenia (Treatment-experienced) in South Korea, Australia, Ukraine, India, Argentina, Mexico, Brazil (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top